Stock BKIT BIOHEMP INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News BioHemp International, Inc.

Equities

BKIT

US09076B1052

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioHemp International Provides Update on Current Status and its CBD Business Model
GL
BioHemp International, Inc. (OTC: BKIT) Acts in Response to SEC and OTC Trading Suspension
GL
Biohemp International, Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2019
CI
BioHemp International (OTC: BKIT) Clarifies Recent 8-K - No Material Change in Share Structure
GL
Biohemp International, Inc. Enters Agreement with American Premium Water Corporation to White Label Cannabidiol Infused Water Utilizing HIPH’s Proprietary Hydro Nano Technology
CI
Daniel Blum, CEO at BioHemp International (OTC: BKIT), discusses new position, CBD opportunities, and long-term company goals with Cannabis Hemp Wire
GL
BioHemp International, Inc. (OTC: BKIT) Announces Deal to Private Label Water From American Premium Water Corporation (OTC: HIPH)
GL
Ludlow Research Initiates Coverage on BioHemp International (BKIT) Based on CBD Distribution Business Model And Assigns A Short Term 'Speculative' Price Target Per Share of $2.50 -$3.50
GL
CBD from Walmart to Kroger: Bigger Distribution Deals In Preparation For A Global CBD Market
NE
BioHemp International, Inc. Appoints Ryan Fishoff as Lead Advisor to the Company
CI
Blake Insomnia Therapeutics, Inc. has Changed its Name to BioHemp International, Inc
CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes
CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended February 28, 2019
CI
Blake Insomnia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2018
CI
Blake Insomnia Therapeutics, Inc. will Change its Ticker to BKIT from BKITD
CI
Blake Insomnia Therapeutics, Inc. Announces Management Changes
CI
Blake Insomnia Therapeutics, Inc. announced that it expects to receive $1 million in funding
CI
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing to Health Canada
CI
Blake Insomnia Therapeutics Appoints Morten Albrechtsen to its Board of Directors
CI
Blake Insomnia Therapeutics Inc. Announces Board Appointments
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BKIT Stock
  4. News BioHemp International, Inc.